OmniAb, Inc. (NASDAQ:OABIW – Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 9,581 shares, a decrease of 33.6% from the May 14th total of 14,433 shares. Based on an average trading volume of 8,727 shares, the short-interest ratio is presently 1.1 days.
OmniAb Trading Down 10.1%
Shares of NASDAQ OABIW opened at $0.09 on Tuesday. OmniAb has a 1 year low of $0.05 and a 1 year high of $0.30. The company’s 50-day moving average is $0.10 and its 200 day moving average is $0.10.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Further Reading
- Five stocks we like better than OmniAb
- This Golden Cross Could Send Urban Outfitters to New Highs
- Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold?
- Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
